Table 1 Characteristic variable
Characteristics | Category | No. of patients (%) |
|---|---|---|
Clinical background | ||
Sex | Male | 35 (64) |
Female | 20 (36) | |
Age (years) | <60 | 28 (51) |
≥60 | 27 (49) | |
Number of liver metastasis | ≤3 | 27 (49) |
>3 | 28 (51) | |
Liver metastasis resection | No | 43 (78) |
Yes | 12 (22) | |
First-line chemotherapy | FOLFOX | 21 (38) |
XELOX | 34 (62) | |
Surgical pathology | ||
Maximum size (cm) | ≤4 | 29 (53) |
>4 | 26 (47) | |
Pathology | Adenocarcinoma | 50 (91) |
Mucinous or signet-ring carcinoma | 5 (9) | |
Differentiation | G1–G2 | 33 (60) |
G3–G4 | 22 (40) | |
Location | Colon | 25 (45) |
Rectum | 30 (55) | |
Tumor stage (T) | 2 | 1 (2) |
3 | 13 (24) | |
4 | 41 (74) | |
Nodal status (N) | 0 | 11 (20) |
1 | 19 (35) | |
2 | 25 (45) | |
Lymphovascular invasion | No | 25 (45) |
Yes | 30 (55) | |
Perineural invasion | No | 28 (51) |
Yes | 27 (49) | |
Extranodal tumor deposits | No | 30 (55) |
Yes | 25 (45) | |
MSI status | dMMR | 4 (7) |
pMMR | 51 (93) | |
Blood biochemical test | ||
NLR | <4 | 41 (75) |
≥4 | 14 (25) | |
PLR | <150 | 31 (56) |
≥150 | 24 (44) | |
ALP | Normal | 46 (84) |
Elevated | 9 (16) | |
LDH | Normal | 44 (80) |
Elevated | 11 (20) | |
Serum CA199 level | Normal | 20 (36) |
Elevated | 35 (64) | |
Serum CEA level | Normal | 12 (22) |
Elevated | 43 (78) | |